Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS

DOI: 10.1002/nau.20485
Neurourology and Urodynamics, 2007, 26, 928-33.

#	Paper	IF	Citations
68	LUTS treatment: future treatment options. *Neurourology and Urodynamics*, **2007**, 26, 934-47	2.3	116
67	The relationship between lower urinary tract symptoms (LUTS), diagnostic indicators of benign prostatic hyperplasia (BPH), and erectile dysfunction in patients with moderate to severely symptomatic BPH. *International Urology and Nephrology*, **2008**, 40, 933-9	2.3	26
66	Lower urinary-tract symptoms and testosterone in elderly men. *World Journal of Urology*, **2008**, 26, 359-64	4	52
65	The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms. *World Journal of Urology*, **2008**, 26, 603-9	4	76
64	Phosphodiesterase type 5 inhibitors improve male lower urinary tract symptoms. *European Urology*, **2008**, 53, 1121-3; discussion 1123-4	10.2	6
63	Rebuttal from Author re: Fran□is Giuliano. Phosphodiesterase Type 5 Inhibitors Improve Male Lower Urinary Tract Symptoms. Eur Urol 2008;53:1121□. *European Urology*, **2008**, 53, 1123-1124	10.2	
62	Daily use of PDE5-inhibitors: the road to happiness?. *European Urology*, **2008**, 54, 28-30	10.2	2
61	Oral phosphodiesterase type 5 inhibitors: nonerectogenic beneficial uses. *Journal of Sexual Medicine*, **2008**, 5, 2502-18	1.1	37
60	Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. *Journal of Urology*, **2008**, 180, 1228-34	2.5	209
59	Emerging drugs for treatment of overactive bladder and detrusor overactivity. *Expert Opinion on Emerging Drugs*, **2008**, 13, 431-46	3.7	18
58	Voiding Function and Dysfunction, Bladder Physiology and Pharmacology, and Female Urology. *Journal of Urology*, **2008**, 180, 630-632	2.5	
57	New insights into the pharmacology of the bladder. *Current Opinion in Urology*, **2008**, 18, 347-52	2.8	16
56	Bladder dysfunction in multiple sclerosis. *Expert Review of Neurotherapeutics*, **2009**, 9, 331-40	4.3	22
55	PDE5 inhibitors for LUTS. *Prostate Cancer and Prostatic Diseases*, **2009**, 12, 316-24	6.2	22
54	Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. *Journal of Sexual Medicine*, **2009**, 6, 544-52	1.1	89
53	Uroflowmetric assessment of acute effects of sildenafil on the voiding of men with erectile dysfunction and symptomatic benign prostatic hyperplasia. *International Urology and Nephrology*, **2009**, 41, 287-92	2.3	19
52	Effect of Tadalafil on prostate haemodynamics: preliminary evaluation with contrast-enhanced US. *Radiologia Medica*, **2009**, 114, 1106-14	6.5	38

51	Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men. *Andrologia*, **2009**, 41, 7-13	2.4	67
50	Medical Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia. *European Urology Supplements*, **2009**, 8, 496-503	0.9	7
49	Sexualidad en la edad geri□trica: disfunci□n er□til, sintomatolog□a urinaria del tracto inferior y posibilidades de tratamiento. *Revista Internacional De Androlog□a*, **2009**, 7, 106-111	0.6	0
48	Fesoterodine: a new antimuscarinic for overactive bladder. *Aging Health*, **2009**, 5, 599-613		
47	Drug Discovery in Non-Life-Threatening Disorders: Erectile Dysfunction, Insomnia, and Smoking Cessation. **2010**, 693-710		
46	Approach and evaluation of neurogenic bladder dysfunction. 61-78		4
45	Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. *Journal of Sexual Medicine*, **2010**, 7, 59-69	1.1	109
44	Detrusor myocyte activity and afferent signaling. *Neurourology and Urodynamics*, **2010**, 29, 97-106	2.3	75
43	Neurogenic bladder dysfunction: pharmacological interventional approaches. 89-111		2
42	Impact of benign prostatic hyperplasia surgery on erectile function. *Urologia Internationalis*, **2010**, 84, 407-12	1.9	3
41	The overactive bladder. *Therapeutic Advances in Urology*, **2010**, 2, 147-55	3.2	9
40	Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. *Journal of Urology*, **2010**, 183, 1092-7	2.5	84
39	Management of overactive bladder. *Nature Reviews Urology*, **2010**, 7, 572-82	5.5	31
38	Overactive bladder. *Maturitas*, **2010**, 66, 257-62	5	17
37	Expression of cAMP-dependent protein kinase isoforms in the human prostate: functional significance and relation to PDE4. *Urology*, **2010**, 76, 515.e8-14	1.6	14
36	Phosphodiesterase Type 5 Inhibitors for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia. *Urological Science*, **2010**, 21, 2-7	0.3	
35	Physiology and Pharmacology of the Bladder. **2011**, 123-138		
34	Effects of testosterone on the lower urinary tract go beyond the prostate: New insights, new treatment options. *Arab Journal of Urology Arab Association of Urology*, **2011**, 9, 147-52	1.7	12

33	Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence. *European Urology*, **2011**, 60, 527-35	10.2	42
32	Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. *European Urology*, **2011**, 60, 1105-13	10.2	135
31	Future Directions in Overactive Bladder Treatment. *Current Bladder Dysfunction Reports*, **2011**, 6, 45-50	0.4	2
30	Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. *Neurourology and Urodynamics*, **2011**, 30, 292-301	3.3	162
29	Cyclic GMP signaling in rat urinary bladder, prostate, and epididymis: tissue-specific changes with aging and in response to Leydig cell depletion. *Reproduction*, **2011**, 142, 333-43	3.8	17
28	Evaluating the significance of cyclic adenosine monophosphate-mediated signaling in human prostate: a functional and biochemical study. *Urology*, **2012**, 80, 952.e9-14	1.6	3
27	Evaluation of Tadalafil effect on lower urinary tract symptoms of benign prostatic hyperplasia in patients treated with standard medication. *International Braz J Urol: Official Journal of the Brazilian Society of Urology*, **2012**, 38, 33-9	2	9
26	Comparison of efficacy for erectile function and lower urinary tract symptoms of tadalafil 20 mg on-demand and 5 mg once daily in patients with erectile dysfunction. *International Journal of Clinical Practice*, **2012**, 66, 813-820	2.9	7
25	Influence of sildenafil on micturition and urethral tone in ovariectomized and non-ovariectomized mice. *Journal of Sexual Medicine*, **2012**, 9, 466-71	1.1	2
24	Common theme for drugs effective in overactive bladder treatment: inhibition of afferent signaling from the bladder. *International Journal of Urology*, **2013**, 20, 21-7	2.3	24
23	The role of phosphodiesterases in bladder pathophysiology. *Nature Reviews Urology*, **2013**, 10, 414-24	5.5	22
22	Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. *Journal of Urology*, **2013**, 189, S135-40	2.5	17
21	2010 Update: Guidelines for the management of benign prostatic hyperplasia. *Canadian Urological Association Journal*, **2013**, 4, 310	1.2	
20	Powerful relaxation of phosphodiesterase type 4 inhibitor rolipram in the pig and human bladder neck. *Journal of Sexual Medicine*, **2014**, 11, 930-941	1.1	10
19	Effect of chronic Sildenafil treatment on the prostate of C57Bl/6 mice. *Tissue and Cell*, **2014**, 46, 439-49	2.7	6
18	Effects of chronic treatment with cilostazol, a phosphodiesterase 3 inhibitor, on female rat bladder in a partial bladder outlet obstruction model. *Urology*, **2014**, 83, 675.e7-11	1.6	4
17	Pharmacological Treatment of Post-Prostatectomy Incontinence: What is the Evidence?. *Drugs and Aging*, **2016**, 33, 535-44	4.7	7
16	Drug Concentration in Rat Plasma, Bladder, and Prostate After Mirodenafil Administration in a Chronic Pelvic Ischemia Model. *Urology*, **2016**, 91, 244.e1-5	1.6	3

15	Effects of Sildenafil, a Phosphodiesterase Type 5 Inhibitor, on the Primary Single Afferent Activity of the Rat Bladder. *LUTS: Lower Urinary Tract Symptoms*, **2017**, 9, 57-61	1.9	2
14	The regulation of transient receptor potential canonical 4 (TRPC4) channel by phosphodiesterase 5 inhibitor via the cyclic guanosine 3′,5′-monophosphate. *Pflugers Archiv European Journal of Physiology*, **2017**, 469, 693-702	4.6	4
13	Effects of daily tadalafil on lower urinary tract symptoms in young men with multiple sclerosis and erectile dysfunction: a pilot study. *Journal of Endocrinological Investigation*, **2017**, 40, 275-279	5.2	16
12	Age Related Differences in Responsiveness to Sildenafil and Tamsulosin are due to Myogenic Smooth Muscle Tone in the Human Prostate. *Scientific Reports*, **2017**, 7, 10150	4.9	5
11	Phosphodiesterase type 4 inhibition enhances nitric oxide- and hydrogen sulfide-mediated bladder neck inhibitory neurotransmission. *Scientific Reports*, **2018**, 8, 4711	4.9	6
10	Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. *The Cochrane Library*, **2018**, 11, CD010060	5.2	8
9	Sildenafil corrects the increased contractility of rat detrusor muscle induced by alprostadil in vitro. *Pharmacological Reports*, **2019**, 71, 659-668	3.9	2
8	Antiglycation and enzyme inhibitory potential of salicylalazine isolated from Micromeria biflora (Buch.-Ham.ex D.Don) Benth. *South African Journal of Botany*, **2021**,	2.9	1
7	Drug Discovery in Erectile Dysfunction and Sleep Disorders. 1-19		
6	Animal models in overactive bladder research. *Handbook of Experimental Pharmacology*, **2011**, 15-43	3.2	46
5	Pharmacologic Management of Lower Urinary Tract Storage and Emptying Failure. **2012**, 1967-2002.e14		3
4	2010 Update: Guidelines for the management of benign prostatic hyperplasia. *Canadian Urological Association Journal*, **2010**, 4, 310-6	1.2	78
3	Physiology and Pharmacology of the Prostate. **2020**, 127-150		1
2	Benign Prostatic Hyperplasia/Obstruction Ameliorated Using a Soluble Guanylate Cyclase Activator.. *Journal of Pathology*, **2021**,	9.4	0
1	Management of Urinary Incontinence Following Radical Prostatectomy: Challenges and Solutions. Volume 19, 43-56		0